Blood steroids are associated with prognosis and fat distribution in endometrial cancer.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
01 2019
Historique:
received: 28 08 2018
revised: 16 10 2018
accepted: 20 10 2018
pubmed: 18 12 2018
medline: 5 2 2019
entrez: 18 12 2018
Statut: ppublish

Résumé

Despite being a hormone dependent cancer, there is limited knowledge regarding the relation between level of steroids in blood and prognosis for endometrial cancer (EC) patients. In this study we investigated plasma levels of 19 steroids using liquid-chromatography tandem mass-spectrometry in 38 postmenopausal EC patients, 19 with long, and 19 with short survival. We explored if estradiol levels were associated with specific abdominal fat distribution patterns and if transcriptional alterations related to estradiol levels could be observed in tumor samples. The plasma steroid levels for DHEA, DHEAS, progesterone, 21 OH progesterone and E1S were significantly increased (all p < 0.05) in patients with long survival compared to short. Estradiol levels were significantly positively correlated with visceral fat percentage (p = 0.035), and an increased expression of genes involved in estrogen related signaling was observed in tumors from patients with high estradiol levels in plasma. Several of the identified plasma steroids represent promising biomarkers in EC patients. The association between increased estradiol levels and a high percentage of visceral fat indicates that visceral fat is a larger contributor to estradiol production compared to subcutaneous fat in this population.

Sections du résumé

BACKGROUND
Despite being a hormone dependent cancer, there is limited knowledge regarding the relation between level of steroids in blood and prognosis for endometrial cancer (EC) patients.
METHODS
In this study we investigated plasma levels of 19 steroids using liquid-chromatography tandem mass-spectrometry in 38 postmenopausal EC patients, 19 with long, and 19 with short survival. We explored if estradiol levels were associated with specific abdominal fat distribution patterns and if transcriptional alterations related to estradiol levels could be observed in tumor samples.
RESULTS
The plasma steroid levels for DHEA, DHEAS, progesterone, 21 OH progesterone and E1S were significantly increased (all p < 0.05) in patients with long survival compared to short. Estradiol levels were significantly positively correlated with visceral fat percentage (p = 0.035), and an increased expression of genes involved in estrogen related signaling was observed in tumors from patients with high estradiol levels in plasma.
CONCLUSION
Several of the identified plasma steroids represent promising biomarkers in EC patients. The association between increased estradiol levels and a high percentage of visceral fat indicates that visceral fat is a larger contributor to estradiol production compared to subcutaneous fat in this population.

Identifiants

pubmed: 30554934
pii: S0090-8258(18)31307-6
doi: 10.1016/j.ygyno.2018.10.024
pii:
doi:

Substances chimiques

Estradiol 4TI98Z838E

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-52

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Ingvild L Tangen (IL)

Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Kristine E Fasmer (KE)

Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway; Section for Radiology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Gonda F Konings (GF)

Department of Gynaecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Arthur Jochems (A)

Department of Gynaecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University, Maastricht, the Netherlands; The D-Lab: Decision Support for Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Universiteitssingel 40, 6229, ER, Maastricht, The Netherlands.

Bert Delvoux (B)

Department of Gynaecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Sofia Xanthoulea (S)

Department of Gynaecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Tomasz Stokowy (T)

Department of Clinical Science, University of Bergen, Bergen, Norway.

Elin Strand (E)

Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Hege F Berg (HF)

Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Seppo Auriola (S)

School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Jone Trovik (J)

Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Merja R Häkkinen (MR)

School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Ingfrid S Haldorsen (IS)

Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway; Section for Radiology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
ENITEC: European Network for Individualised Treatment of Endometrial Cancer (within the European Society of Gynaecological Oncology.

Camilla Krakstad (C)

Department of Gynaecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway. Electronic address: camilla.krakstad@uib.no.

Andrea Romano (A)

Department of Gynaecology and Obstetrics, GROW - School for Oncology & Developmental Biology, Maastricht University, Maastricht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH